Decision Support in Florida

Visual Medica is a cloud-based PACS (Picture Archiving and Communication System) and RIS (Radiology Information System) software provider founded in 1998, serving radiology centers and diagnostic imaging facilities across Latin America. The company offers fully web-based, cloud-hosted or on-premise solutions including VM PACS VNA for DICOM image storage and visualization, VM RIS Gestión ERP for integrated radiology workflow and administrative management, VM Medical Workstation for diagnostic image processing, and VM Clinical Viewer for remote access. Visual Medica's flagship offering is its AI Marketplace—an integrated platform combining RIS, PACS, medical administration, and artificial intelligence-powered diagnostic support tools, including VM Speech (medical speech recognition) and structured reporting assistance. The platform is designed to streamline imaging workflows, improve diagnostic accuracy, and enhance operational efficiency. With over 1,500 installations across Latin America and FDA clearance, Visual Medica serves hospitals, diagnostic centers, and imaging practices of varying sizes.

Brain Tunnelgenix Technologies Corporation (BTT™ Corp.) is a MedTech innovator specializing in non-invasive, continuous brain temperature monitoring through proprietary brain thermal tunnel technology. Founded on discoveries by Dr. Marc Abreu (Harvard Medical School, Yale School of Medicine), BTT develops FDA-cleared devices and wearable systems that capture real-time brain thermodynamic signatures using advanced microsensors and artificial intelligence. The BTT™ Abreu 700 system represents the first clinically accurate measurement of human brain temperature without corrective factors. The company's integrated platform combines brain thermodynamics, IoT connectivity, and predictive AI models to support diagnosis, monitoring, and therapeutic applications across infectious diseases, neurodegenerative conditions (Alzheimer's, Parkinson's, Multiple Sclerosis), cancer, stroke risk, surgical outcomes, sleep optimization, and performance enhancement. Applications span clinical settings, hospital environments, home monitoring, and occupational wellness programs.

NOVODX Corporation develops handheld at-home diagnostic screening infrastructure and consumer health platforms. The company's primary product, GoldN Companion, is a portable, smartphone-connected device designed to perform biomarker-based health screenings in 15 minutes or less. The platform supports multiple indications and features an AI assistant that guides users through screening procedures, contextualizes results, and maintains longitudinal health records. The device operates without internet connectivity for testing but requires Bluetooth and mobile app connectivity for data syncing and AI-powered insights. Test cassettes are single-use; the reusable handheld platform supports multiple biomarker analyses. NOVODX emphasizes practical, accessible design suitable for home use, field programs, and resource-limited settings. The company maintains HIPAA-compliant cloud infrastructure for data storage and user management. GoldN Companion is currently under development and not FDA-cleared or available for commercial sale in the US or internationally as of the site's last update. The platform is designed for consumer and professional deployment, with a stated mission to make health screenings simple, accessible, and trustworthy. Founded by CEO Nancy Torres, NOVODX positions itself at the intersection of consumer health technology and point-of-care diagnostics, targeting households and healthcare professionals.

Fairtility Ltd. develops CHLOE, a transparent AI-powered decision support platform designed for reproductive medicine and IVF clinics. CHLOE provides explainable artificial intelligence that analyzes embryo quality, oocyte (egg) quality, lab performance metrics, and treatment progress. The platform monitors embryo development using biomarkers to deliver objective AI-driven assessment and ranking, removing subjectivity from embryo selection for transfer. For egg freezing and fertility preservation, CHLOE assesses oocyte potential from single images to support counseling and identify quality issues. The system automatically tracks lab performance KPIs to detect deviations early and support operational efficiency. CHLOE transforms complex laboratory data into clear visual insights, enabling transparent patient conversations from initial consultation through transfer while providing physicians real-time progress visibility without manual updates. The platform emphasizes transparent AI methodology, making clinical reasoning visible so embryologists and physicians can validate insights against their own expertise. CHLOE integrates securely across lab and clinic systems to streamline workflows, reduce manual data management, and improve clinic positioning. The company has partnerships with major academic medical centers and fertility clinics including Mayo Clinic, Memorial Sloan Kettering, Cleveland Clinic, Hadassah Medical Center, and Weill Cornell Medicine. Fairtility has received industry recognition including MedTech Breakthrough Awards.

Aventusoft, LLC is a Boca Raton, Florida-based medical technology company specializing in signal detection analysis and AI-driven digital health platforms since 2010. The company develops innovative solutions focused on cardiac monitoring, clinical decision support, and decentralized clinical research. Primary product lines include Hemotag, a non-invasive cardiac monitoring device paired with AI analytics to reduce reliance on invasive cardiac imaging and implantable devices; CarePear, a digital health platform connecting patients and physicians with US-based sub-specialists through AI-enabled telemedicine; and Trialogy, an AI-driven platform for decentralized clinical trials that streamlines life science research. Aventusoft has received recognition from the NIH (RADx Tech for Maternal Health Challenge), DARPA, American College of Cardiology (ACC Innovation Showcase Award 2021 and 2023), and multiple design and innovation awards. The company demonstrated 146% two-year revenue growth and ranked No. 112 on Inc. Magazine's 2023 Southeast Region fastest-growing private companies list. Products target cardiac care, maternal health, specialist access, and clinical research domains, with regulatory focus on maternal health applications and AI-driven diagnostics.

inHEART develops an AI-enabled digital twin platform for cardiac care, specializing in image-guided ablation procedures for ventricular tachycardia (VT) and other arrhythmias. The company's core offering is a proprietary segmentation algorithm that analyzes CT and MR images to create detailed 3D anatomical cardiac models, enabling precise identification of arrhythmogenic tissue and substrate characterization. The platform integrates seamlessly with all major electroanatomic mapping (EAM) systems for real-time procedural guidance. Clinical evidence demonstrates 60% reduction in procedure time and 38% reduction in recurrence rates for VT ablations. inHEART serves 300+ partner hospitals across 40+ countries, with 7,500+ supported cases. The company maintains regulatory compliance including SOC 2 and HIPAA certifications. Based in France (Bordeaux/Pessac) with a US office in Cambridge, MA, inHEART operates at the intersection of advanced imaging analytics, AI, and interventional cardiology. The platform has been featured in major cardiac electrophysiology symposia and publications, with endorsements from leading academic electrophysiologists. Recent funding (2024) and board leadership appointments signal continued investment in platform expansion and global market penetration. Target users include cardiac electrophysiologists, interventional cardiologists, and hospital EP labs managing complex arrhythmias.

Ositech Communications, Inc. is a mobile wireless data communications company headquartered in Canada's Silicon Valley that designs and manufactures customized connectivity solutions for healthcare, emergency services, and public safety sectors. The company specializes in device connectivity accessories, mobile wireless routers, and AI-enabled clinical decision-support platforms that integrate with hospital systems, EMS operations, fire rescue, and police departments. Their product portfolio includes: Device Connectivity (customized data accessories for medical device communications), Routica (5G/Wi-Fi 6 mobile routers for emergency vehicles and transportation fleets), Connected4Life (AI-powered sudden cardiac arrest detection and AED cabinet management for out-of-hospital settings), and RRT CoPilot (AI-driven early warning system for hospital-based patient deterioration detection). Products leverage advanced wireless technologies including 5G cellular, Wi-Fi 6, GNSS, and StarLink integration. Ositech's solutions are designed as integrated accessories compatible with third-party medical equipment and hospital ecosystems, with custom adaptation available for specific clinical and operational requirements. The company serves hospitals, EMS organizations, fire rescue agencies, and public health systems across North America, focusing on reducing time-to-intervention in cardiac emergencies and improving clinical outcomes through real-time data connectivity and AI-powered monitoring.

Mel-Mont Medical Inc is a clinical diagnostics and molecular technology company specializing in HPV-related cancer detection and prevention. The company develops patented, non-invasive self-sampling medical devices coupled with proprietary comprehensive molecular testing platforms for early identification of high-risk human papillomavirus (HR-HPV) infections. The company operates three primary product divisions: (1) Medical Devices—user-friendly, patented devices for HPV-related cancer prevention; (2) In Vitro Diagnostics (PreTect division)—ISO 13485-certified molecular assays for nucleic acid amplification and HPV-mRNA testing with proprietary laboratory services; (3) Sample Preparation Reagents—molecular testing reagents and transport media for sample handling. Mel-Mont Medical maintains a rigorous R&D pipeline following a six-stage development methodology: concept identification, usage characterization, design and development, pilot production and validation, regulatory prelaunch monitoring, and market launch with post-market surveillance. The company conducts preclinical and clinical trials to validate devices before market introduction and emphasizes clinically proven molecular biology technologies. Products are manufactured in compliance with applicable standards. The company serves international markets including the United States, Mexico, Spain, Norway, and Colombia, with distribution and manufacturing partnerships in select regions.

Neurotone AI develops Lace AI Pro, a clinically validated auditory training platform designed to enhance hearing comprehension and cognitive processing in patients with hearing loss. The platform combines 20+ years of peer-reviewed science with cutting-edge artificial intelligence to train patients' brains to process and understand speech and sound more effectively, complementing traditional hearing aids rather than replacing them. Lace AI Pro is built on the legacy of LACE (Listening and Communication Enhancement), which has been taught in audiology programs for decades and is recognized globally as one of the leading auditory training tools. The software is supported by 10 clinical trials involving thousands of patients, demonstrating efficacy in reducing hearing aid returns, improving task scores, and enhancing quality of life. The platform is used by hundreds of clinics worldwide and is offered through a partner certification program for audiologists and hearing care practices. Key clinical benefits include improvement in cognition and working memory, helping patients maintain engagement and supporting healthy aging. The company operates a provider partnership model with simple practice billing integration and maintains a clinic locator to connect patients with certified providers.

UpRight Science develops FDA-cleared balance assessment and fall-risk detection technology for clinical and research use. The company's core offering is a medical-grade, AI-driven platform that quantifies balance and gait dynamics to identify fall risks, neurological decline, and medication side effects. Their technology integrates machine learning algorithms trained on biomechanical datasets to provide clinicians and researchers with actionable insights for patient stratification and early intervention. The platform is validated in clinical trials and marketed as addressing balance as "the sixth vital sign"—positioning fall prevention as a critical health metric alongside traditional vital signs. UpRight Science targets healthcare providers, physical therapy clinics, geriatric care facilities, and research institutions. The technology combines motion analysis with predictive analytics to detect deviations linked to neurodegenerative diseases and other conditions affecting balance and gait. The company emphasizes evidence-based development leveraging decades of balance science research. Their go-to-market approach includes direct sales to clinical and research institutions via demonstrations and proof-of-concept studies.

MRS Health, Inc. is an AI-enabled population health management company specializing in musculoskeletal disorder (MSD) prevention, diagnosis, and treatment. The organization delivers an integrated care program combining predictive analytics, functional restoration therapy, and connected home rehabilitation devices. MRS Health uses proprietary algorithms and supervised learning AI to identify at-risk populations from medical and pharmacy claims data, enabling early intervention and cost mitigation. The company operates center-based functional restoration programs staffed by physicians, physical therapists, exercise physiologists, and health coaches, utilizing biomechanically optimized equipment and IT platforms. For distributed workforces, MRS Health provides telehealth-enabled connected strengthening devices for spine, back, and neck rehabilitation—devices designed for home use that deliver clinically proven outcomes. The company targets leading healthcare cost drivers including musculoskeletal conditions, opioid use disorder, mental health, diabetes, and durable medical equipment expenses, with demonstrated ROI exceeding 3.5:1 for employer-sponsored health plans.